Milan Facilities ANYTHING IS POSSIBLE Any size company. Any phase. Any process. Any location in the world. Whatever your need, we are the CDMO that can get it done. Together, we have the power to change lives by transforming your vision into reality. With state-of-the-art clinical and commercial manufacturing facilities across the United States, Europe and Asia, AGC Biologics has the capacity and flexibility to meet your individual manufacturing needs. We're here for you, wherever you are. Milan facility Modalities CELL THERAPYVIRAL VECTORS (Plasmid DNA offered from our Heidelberg site) Contact Us Milan Via Olgettina, 58 20132 Milan, Italy Tel: +39 02 21277.1 Fax: +39 02 21277.325 Email: contactus@agcbio.com General Manager Luca Alberici Now Hiring We’re looking for talented individuals – just like you – to join our team in Milan. We can't wait to meet you. Learn more and apply now: VIEW CURRENT JOB OPENINGS IN MILAN MILAN FACILITIES The two facilities that make up AGC Biologics' Milan campus were the first cell and gene therapy facilities approved in Europe for GMP manufacturing of clinical and commercial supply (2003 and 2015, respectively). AGC Biologics brings technical expertise to develop and optimize every aspect of cell therapy and viral vector gene therapy. Our services range from the production of plasmid DNA (at our Heidelberg facility), necessary for the transfection of cell production, to the engineering of cells through the use of produced viral vectors. Our technical know-how allows us to bring small-scale platforms to scalable industrial manufacturing, ensuring process robustness and commercial viability. With experience manufacturing four commercial products, we are the only cell and gene therapy CDMO which has brought its own product to the market (Zalmoxis®). [ GMP/QC Equipment and Technology , Development Area Equipment and Technology , Ongoing Expansion ] ABOUT CAPABILITIES RESOURCES FACILITIES NEWS & EVENTS LEGAL & COMPLIANCE CONTACT US Follow us on LinkedIn Follow us on Twitter Follow us on Facebook NEWS AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer AGC Biologics Expands pDNA and mRNA Manufacturing Capacity AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings EVENTS Cell & Gene Meeting on the Mesa, October 12-14, 2021 AGC Biologics is Attending BIO Asia-Taiwan July 23-26, 2021 Presenting Our Biological and Cell & Gene Therapy Capabilities AGC Biologics is Attending ASGCT May 11-14, 2021 and Presenting Our Scalable LVV Production Process and Large-Scale AAV Manufacturing Development Data AGC Biologics is Attending Meeting on the Med, April 6-9, 2021 FACILITIES SEATTLE, WASHINGTON (Headquarters) BOULDER, COLORADO LONGMONT, COLORADO COPENHAGEN, DENMARK HEIDELBERG, GERMANY MILAN, ITALY CHIBA, JAPAN ©2021 AGC Biologics. All Rights Reserved. Website Privacy Policy